Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)
CNY 23.75
(-0.88%)
CNY 23.75
(-0.88%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 549.13 Million CNY | -59.85% |
| 2022 | 1.36 Billion CNY | 97.68% |
| 2021 | 691.89 Million CNY | -6.51% |
| 2020 | 740.09 Million CNY | 45.46% |
| 2019 | 508.78 Million CNY | 23.49% |
| 2018 | 411.99 Million CNY | 58.09% |
| 2017 | 260.6 Million CNY | 64.19% |
| 2016 | 158.72 Million CNY | 30.32% |
| 2015 | 121.79 Million CNY | 33.12% |
| 2014 | 91.49 Million CNY | 107.82% |
| 2013 | 44.02 Million CNY | 47.41% |
| 2012 | 29.86 Million CNY | 29.43% |
| 2011 | 23.07 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 90.88 Million CNY | -32.34% |
| 2024 Q2 | 134.32 Million CNY | -42.99% |
| 2024 Q1 | 235.59 Million CNY | 172.78% |
| 2023 FY | 549.13 Million CNY | -59.85% |
| 2023 Q1 | 232.03 Million CNY | 443.87% |
| 2023 Q4 | 86.36 Million CNY | 15.85% |
| 2023 Q2 | 156.18 Million CNY | -32.69% |
| 2023 Q3 | 74.55 Million CNY | -52.27% |
| 2022 Q2 | 233.45 Million CNY | -77.73% |
| 2022 Q1 | 1.04 Billion CNY | 41815.9% |
| 2022 Q4 | -67.47 Million CNY | -200.75% |
| 2022 Q3 | 66.97 Million CNY | -71.31% |
| 2022 FY | 1.36 Billion CNY | 97.68% |
| 2021 Q4 | 2.5 Million CNY | -94.95% |
| 2021 Q1 | 175.95 Million CNY | 225.6% |
| 2021 Q2 | 463.93 Million CNY | 163.67% |
| 2021 FY | 691.89 Million CNY | -6.51% |
| 2021 Q3 | 49.5 Million CNY | -89.33% |
| 2020 Q3 | 133.67 Million CNY | -69.01% |
| 2020 Q2 | 431.33 Million CNY | 256.35% |
| 2020 Q1 | 121.04 Million CNY | -13.07% |
| 2020 FY | 740.09 Million CNY | 45.46% |
| 2020 Q4 | 54.04 Million CNY | -59.57% |
| 2019 Q3 | 107.06 Million CNY | -36.56% |
| 2019 Q2 | 168.77 Million CNY | 80.14% |
| 2019 FY | 508.78 Million CNY | 23.49% |
| 2019 Q4 | 139.24 Million CNY | 30.05% |
| 2019 Q1 | 93.69 Million CNY | -24.55% |
| 2018 Q3 | 79.26 Million CNY | -42.95% |
| 2018 Q2 | 138.94 Million CNY | 99.64% |
| 2018 Q1 | 69.59 Million CNY | -11.9% |
| 2018 FY | 411.99 Million CNY | 58.09% |
| 2018 Q4 | 124.18 Million CNY | 56.66% |
| 2017 Q4 | 79 Million CNY | 36.79% |
| 2017 Q1 | 34.14 Million CNY | -5.75% |
| 2017 Q2 | 89.69 Million CNY | 162.67% |
| 2017 FY | 260.6 Million CNY | 64.19% |
| 2017 Q3 | 57.75 Million CNY | -35.62% |
| 2016 FY | 158.72 Million CNY | 30.32% |
| 2016 Q4 | 36.23 Million CNY | -2.68% |
| 2016 Q3 | 37.23 Million CNY | -35.3% |
| 2016 Q2 | 57.54 Million CNY | 107.58% |
| 2016 Q1 | 27.72 Million CNY | -24.64% |
| 2015 FY | 121.79 Million CNY | 33.12% |
| 2015 Q4 | 36.78 Million CNY | 63.9% |
| 2015 Q3 | 22.44 Million CNY | -45.68% |
| 2015 Q2 | 41.31 Million CNY | 94.38% |
| 2015 Q1 | 21.25 Million CNY | 34.82% |
| 2014 Q1 | 21.4 Million CNY | 0.0% |
| 2014 Q4 | 15.76 Million CNY | -34.37% |
| 2014 Q3 | 24.02 Million CNY | -15.01% |
| 2014 Q2 | 28.26 Million CNY | 32.06% |
| 2014 FY | 91.49 Million CNY | 107.82% |
| 2013 FY | 44.02 Million CNY | 47.41% |
| 2012 FY | 29.86 Million CNY | 29.43% |
| 2011 FY | 23.07 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 998.13 Million CNY | 44.983% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion CNY | 77.919% |
| Dirui Industrial Co.,Ltd. | 296.87 Million CNY | -84.973% |
| Beijing Strong Biotechnologies, Inc. | 593.87 Million CNY | 7.533% |
| Medicalsystem Biotechnology Co., Ltd. | 279.11 Million CNY | -96.741% |
| Maccura Biotechnology Co.Ltd | 331.14 Million CNY | -65.83% |
| Guangdong Hybribio Biotech Co.,Ltd. | 42.59 Million CNY | -1189.065% |
| BGI Genomics Co., Ltd. | 150.64 Million CNY | -264.514% |
| Amoy Diagnostics Co., Ltd. | 301.24 Million CNY | -82.288% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -135.82 Million CNY | 504.302% |